Literature DB >> 35842925

ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.

Konstantine Halkidis1, X Long Zheng2,3.   

Abstract

ADAMTS13, a plasma metalloprotease that cleaves von Willebrand factor, is crucial for normal hemostasis. Acquired autoantibody-mediated deficiency of plasma ADAMTS13 results in a potentially fatal blood disorder, immune thrombotic thrombocytopenic purpura (iTTP). Plasma ADAMTS13 protease appears to exist in multiple conformations. Under physiological conditions, plasma ADAMTS13 exists predominantly in its "closed" conformation (or latent form), which may be activated by lowering pH, ligand binding, and binding of an antibody against the distal domains of ADAMTS13. In patients with iTTP, polyclonal antibodies target at various domains of ADAMTS13. However, nearly all inhibitory antibodies bind the spacer domain, whereas antibodies that bind the distal C-terminal domains may activate ADAMTS13 through removing its allosteric inhibition. Additionally, the anti-C-terminal antibodies may alter the potency of inhibitory antibodies towards ADAMTS13 activity. This review summarizes some of the most recent knowledge about the ADAMTS13 conformation and its mechanism of inhibition by its autoantibodies.
© 2022 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  ADAMTS13; TTP/HUS; activation; autoantibody; inhibition

Mesh:

Substances:

Year:  2022        PMID: 35842925      PMCID: PMC9587499          DOI: 10.1111/jth.15822

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   16.036


  75 in total

Review 1.  Plasma exchange in the management of thrombotic thrombocytopenic purpura.

Authors:  Gail Rock
Journal:  Vox Sang       Date:  2002-08       Impact factor: 2.144

2.  Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Elien Roose; An-Sofie Schelpe; Edwige Tellier; György Sinkovits; Bérangère S Joly; Charlotte Dekimpe; Gilles Kaplanski; Maelle Le Besnerais; Ilaria Mancini; Tanja Falter; Charis Von Auer; Hendrik B Feys; Marienn Reti; Heidi Rossmann; Aline Vandenbulcke; Inge Pareyn; Jan Voorberg; Andreas Greinacher; Ygal Benhamou; Hans Deckmyn; Rob Fijnheer; Zoltan Prohászka; Flora Peyvandi; Bernhard Lämmle; Paul Coppo; Simon F De Meyer; Agnès Veyradier; Karen Vanhoorelbeke
Journal:  Blood       Date:  2020-07-16       Impact factor: 22.113

3.  Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.

Authors:  Xinglong Zheng; Kenji Nishio; Elaine M Majerus; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-06-05       Impact factor: 5.157

4.  A study of plasma exchange in TTP. The Canadian Apheresis Study Group.

Authors:  G Rock; K Shumak; R Nair
Journal:  Prog Clin Biol Res       Date:  1990

5.  Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  F Peyvandi; M Scully; J A Kremer Hovinga; P Knöbl; S Cataland; K De Beuf; F Callewaert; H De Winter; R K Zeldin
Journal:  J Thromb Haemost       Date:  2017-06-05       Impact factor: 5.824

Review 6.  Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Bernhard Lämmle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

7.  Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.

Authors:  Sheng-Yu Jin; Christopher G Skipwith; X Long Zheng
Journal:  Blood       Date:  2010-01-14       Impact factor: 22.113

8.  Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Mari R Thomas; Rens de Groot; Marie A Scully; James T B Crawley
Journal:  EBioMedicine       Date:  2015-06-11       Impact factor: 8.143

9.  Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Louis Deforche; Claudia Tersteeg; Elien Roose; Aline Vandenbulcke; Nele Vandeputte; Inge Pareyn; Elien De Cock; Hanspeter Rottensteiner; Hans Deckmyn; Simon F De Meyer; Karen Vanhoorelbeke
Journal:  PLoS One       Date:  2016-08-01       Impact factor: 3.240

10.  Crystal structure of ADAMTS13 CUB domains reveals their role in global latency.

Authors:  H J Kim; Y Xu; A Petri; K Vanhoorelbeke; J T B Crawley; J Emsley
Journal:  Sci Adv       Date:  2021-04-16       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.